📌 Key Takeaways
- Topic: Silica Particle Size Guide: How D50, Mesh and Microns Affect Performance
- Keywords: silica filler for CCL
- Published: 2026-11-20 02:42:50
- Field: Silica (SiO₂) raw materials · Inorganic non-metallic materials · Chemicals
Silica Supplier Turkey: Market Overview, Producers and Import Options
- Silica Aerogel Powder: Properties, Applications and How It Compares to Other Insulators
- 93. Zhang W., Li G., Xiao C., Chang X., Sun Y., Fan W., Tian B., Gao D., Xiao Y., Wu X., et al. Mesoporous Silica Carrier-Based Composites for Taste-Masking of Bitter Drug: Fabrication and Palatability Evaluation. AAPS PharmSciTech. 2022;23:75. doi: 10.1208/s12249-022-02227-7. [ DOI ] [ PubMed ] [ Google Scholar ]
- Silica Manufacturers List: Global and Chinese Producers by Product Type
- This supports that the release rate depends on several components, among others, influenced by the pore size, the pore structure, the amount of drug loaded, the solubility of the API, and the resulting interaction between the carrier and the transported molecules [ 2 ]. By modifying these, the release kinetics can be controlled to a small extent, but a considerable influence can only be attained by surface functionalization of the mesopores. The following table contains some experimental data in terms of drug release in case of the previously shown APIs ( Table 2 ).
- What Is the Refractive Index of Silica? Values for Fused Silica, Quartz and Amorphous Silica
- Silicon Dioxide in Supplements: Purpose, Safety and Dosage Limits
- 59. Ritger P.L., Peppas N.A. An effortless equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J. Control. Release. 1987;5:23-36. doi: 10.1016/0168-3659(87)90034-4. [ DOI ] [ PubMed ] [ Google Scholar ]
Silica Exporter Guide: Export Documents, Packaging and Shipping Terms
What is silica (SiO₂)?
CMP slurry silica
What is the difference between fumed silica and precipitated silica?
silica excipient The skin is our largest organ, which consists of three layers: the epidermis, dermis, and hypodermis. Owing to its big surface zone, it also serves as an essential gateway for drug administration [ 25 ], which is fitting for both local (dermal) or systemic (transdermal) therapy [ 25, 56 ]. In spite of the popularity of this administration route, it is a challenge to get the API into deeper layers of the skin. The outermost layer of the epidermis, the stratum corneum, is the biggest hurdle to molecular penetration [ 25, 56 ]. However, the molecules must be absorbed through the capillaries of the dermis to achieve a systemic impact, which can be facilitated employing nanocarriers [ 56 ]. In addition, sweat glands or hair follicles can be effective alternative routes for the molecules to enter the deeper layers of the skin [ 25, 56 ]. In summary, it can be called as the transappendageal route. Among physicochemical properties, particle size is one of the most vital factors influencing absorption. Particles in the range between 200 and 300 nm are suitable for local treatment of the skin in diseases such as atopic dermatitis [ 25 ] since particles larger than 75 nm do not pass through the stratum corneum [ 25 ]. Smaller particles (approximately 50 nm) are suitable for systemic treatment [ 25 ], and on the whole, it can be said that nanoparticles with a diameter smaller than 25 nm can penetrate the skin most effectively, so they can be used for transdermal drug administration with an appropriate formulation [ 56 ]. By controlling the size of the nanocarrier, they penetrate to different depths in the skin. From the element of surface characteristics, cationic amino-functionalized MSNs show more efficient penetration into deeper layers of the skin than the particles with anionic surfaces of the same size [ 25 ]. The use of MSNs as a drug carrier may improve aqueous solubility, stability, and skin penetration of the drug [ 61 ]. In a research, gels containing MSN were prepared by employing distilled water to form the base, adding the gelling agent (Poloxamer 407), and adding HPMC to enhance the viscosity [ 83 ]. In another publication, MSN containing oleogels were prepared with sunflower oil and the addition of colloidal silicon dioxide as a gelling agent [ 61 ]. According to in vitro experiments, the gel matrix also affected the drug release kinetics [ 61, 83 ]. Slower drug release was observed in the case of gels containing loaded MSNs, compared to the free carriers, and the outcomes demonstrated close to zero-order release kinetics [ 61 ]. According to in vitro biocompatibility studies, this gel complex did not show any evidence of cytotoxicity on dermal fibroblast cells. Moreover, according to in vivo dermal safety studies, it has been proven that this preparation does not cause skin irritation during application, and so this formulation can be considered a safe product [ 61 ].
What drives silica raw material prices?
Imerys silica
/news/article.htmlDisclaimer: Prices and data are for reference only and do not constitute purchasing or investment advice. Please credit the source when republishing.